fT>MIC sufficient (n=14) | fT>MIC not sufficient (n=13) | P value | |
Pulmonary function at exacerbation,* predicted mean (SE) | (n=12 with PFTs) | (n=11 with PFTs) | |
% predicted FEV1† | 76.7 (6.29) | 87.2 (6.74) | 0.296 |
% predicted FVC | 82.2 (7.00) | 93.7 (7.50) | 0.368 |
% predicted FEF25–75 | 77.9 (11.43) | 67.3 (10.68) | 0.588 |
Bacterial and viral pathogens | |||
MRSA positive,‡ n (% yes) | 1 (7) | 2 (15) | 0.496 |
MSSA positive,‡ n (% yes) | 3 (21) | 1 (8) | 0.315 |
Pseudomonas aeruginosa positive,‡ n (% yes) | 4 (29) | 5 (38) | 0.586 |
Achromobacter xylosoxidans positive,‡ n (% yes) | 1 (7) | 0 (0) | 0.326 |
Stenotrophomonas maltophilia positive,‡ n (% yes) | 1 (7) | 0 (0) | 0.326 |
Haemophilus influenzae positive,‡ n (% yes) | 1 (7) | 0 (0) | 0.290 |
No pathogen present,‡ n, (% yes) | 7 (50) | 5 (38) | 0.547 |
Respiratory pathogen panel‡ | (n=6 tested) | (n=5 tested) | |
Rhino/enterovirus (n) | 2 | 1 | 0.999 |
Negative (n) | 4 | 4 | |
PEx treatments | |||
Primary beta-lactam antibiotic,‡ n (%) | 0.124 | ||
Ceftriaxone | 2 (14) | 0 (0) | |
Ceftazidime | 8 (57) | 4 (31) | |
Cefepime | 1 (7) | 4 (31) | |
Piperacillin–tazobactam | 1 (7) | 4 (31) | |
Meropenem | 2 (14) | 1 (8) | |
Narrow spectrum,‡ n (% yes) | 11 (79) | 8 (62) | 0.333 |
Concurrent aminoglycosides,‡ n (% yes) | 8 (57) | 9 (69) | 0.516 |
Concurrent MRSA-directed therapy,‡ n (% yes) | 3 (21) | 2 (15) | 0.686 |
Total days of antibiotic therapy,* predicted mean (SE) | 18.2 (1.57) | 13.4 (1.66) | 0.086 |
Steroids given,‡ n (% yes) | 5 (36) | 8 (62) | 0.180 |
fT>MIC,* mean (SE) | 87.5 (6.4) | 28.2 (6.8) | <0.001 |
Creatinine clearance,§* mean (SE) | 148.1 (15.8) | 224.9 (16.7) | 0.002 |
*General linear model with Gaussian family and identity link, controlling for demographic characteristics.
†Square transform.
‡χ2.
§Log transform.
FEF25–75, forced expiratory flow 25–75; FEV1, forced expiratory volume in one second; fT>MIC, time above the minimum inhibitory concentration; FVC, forced vital capacity; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PEx, pulmonary exacerbation; PFT, pulmonary function test.